Brought to you by 
Amgen, Merck ally in combination trials
11 Oct 2021
Executive Summary
Amgen Inc. and Merck & Co. Inc. are teaming up to conduct a Phase Ib/III safety and efficacy trial of Amgen's CD19 antagonist Blincyto (blinatumomab) in combination with Merck's PD-1 receptor antagonist Keytruda (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen, Merck ally in combination trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice